Fundraising FoxBaidu Ventures — 2018 Investments
4 investments dated 2018 · listed companies and verified rows first · show all
Atomwise uses artificial intelligence and machine learning to discover novel small-molecule drugs, with a current focus on developing treatments for immune and inflammatory diseases.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Izhar Wallach(Executive Officer, Director)inAbraham Heifets(Executive Officer, Director, Promoter)Yan Zhao(Executive Officer)inStephen Worland(Executive Officer, Director)
BoardRobert Mittendorff(Director)inAdam Seabrook(Director)in
Co-investorsAurum Venture PartnersB Capital GroupCerity Partners VenturesCreative Destruction Lab (CDL)Draper AssociatesMission and Market+7 more
.jpeg){kind=logo}
Kebotix uses artificial intelligence, machine learning, and laboratory automation to discover and develop new materials and molecules.
AI & Machine LearningDeep TechNew MaterialsCambridge, US
Dennis Sheberla(Executive Officer)inSemion Saykin(Executive Officer)Alan Aspuru-Guzik(Executive Officer)inAshish Kulkarni(Chairman and CEO)in
BoardTong Hui(Director)Andrew Krowne(Director)in
Co-investorsArcTern VenturesBantam GroupEmbark VenturesFlybridge Capital PartnersOne Way VenturesPropagator Ventures+5 more
Numerion combines drug discovery expertise with machine learning and computational chemistry.
AI & Machine LearningBiotechHealthtechMedical DevicesSan Francisco, US
Alex Levy(Founder)inIzhar Wallach(Founder)inSteve Worland(CEO)inPamela Tsuruda(VP, Biology)Mark Sabat(VP, Medicinal Chemistry)inKate Stafford(VP, Machine Learning)in
Co-investorsB Capital GroupB4 CapitalColorcon VenturesDCVC (Data Collective)Dolby Family VenturesNEXT Canada+12 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
SimpleMachines
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.